

1

2

3

Quality of Life Impacts from Rotavirus Gastroenteritis on Children and Their Families in the UK.

4

5

Robin Marlow^{a,b}, Adam Finn^{a,b}, Caroline Trotter^c

6

^a Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

7

^b Schools of Clinical Sciences & Cellular & Molecular Medicine, University of Bristol, UK

8

^c Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, UK

9

Corresponding author: robin.marlow@bristol.ac.uk

10

11 **Abstract**

12 Aims

13 Rotavirus vaccines (RV) are safe and effective but demand significant investment of healthcare
14 resource. In countries with low mortality due to rotavirus, a key component to assessing cost-
15 effectiveness is quantifying the Health Related Quality of Life (HRQoL) lost due to rotavirus acute
16 gastroenteritis (RVAGE).

17 Methods

18 Families with children less than six years old with gastroenteritis were recruited from attendees to
19 Bristol Children's Hospital Emergency Department. Stools were tested for viral causes of
20 gastroenteritis. Children's HRQoL was assessed at presentation using Health Utilities Index 2 (HUI2)
21 with visual analogue scale (VAS). The effect of the child's illness on the HRQoL of up to two adult
22 carers was assessed using EQ-5D-5L. Families completed a daily symptom diary to assess time to
23 recovery and within-family transmission.

24 Results

25 127 families consented to take part, 84(65%) had rotavirus as the cause of illness.
26 At the time of attendance, mean paediatric HRQoL with RVAGE was 0.74(HUI2) and 0.42(VAS).
27 Primary / secondary carer's HRQoL was 0.68/0.80 (EQ5D) or 0.70/0.79 (VAS). The mean number of
28 QALYs lost due to RVAGE was 3.1-3.5 per thousand children and 7.7-8.7 per thousand family units.
29 In 52% of RVAGE families at least one other member developed a secondary case of gastroenteritis.
30 For working parents, 69% missed work, for a mean of 2.8 days (95% CI 2.3-3.4).

31 Conclusions

32 We have found the HRQoL loss associated with RVAGE in children and their carers to be significantly
33 higher than estimates used for all RV medical attendances in UK cost-effectiveness calculations.

34 **Keywords:** Rotavirus; Quality of life; Great Britain; Rotavirus Vaccines; Economic Evaluation

35 **Introduction**

36 Rotavirus is the commonest cause of gastroenteritis in childhood and most children will have
37 suffered from it at least once by the time they are five years old.[1] Although prevalent in all
38 countries, the burden of rotavirus is far from equitable. In developing countries with limited access
39 to healthcare, it is estimated to lead to the deaths of half a million children under the age of five per
40 year.[2] In the early 1980s, vaccination was identified as the only feasible method of controlling
41 rotavirus.[3] A worldwide concerted effort to develop a vaccine has culminated in the licensure of
42 two safe and effective formulations in 2006. The WHO has recommended that all countries[4]
43 introduce RV vaccine into their childhood vaccination schedules.

44 With the support of international agencies and discounted vaccine prices, in countries with high
45 levels of mortality due to rotavirus, the justification for vaccination is clear. But in those countries
46 where mortality is rare, such as in the United Kingdom (UK), [5] a more formal approach to assessing
47 cost-effectiveness is required. In the UK new vaccines are assessed by the Joint Committee for
48 Vaccination and immunisation (JCVI) using methods based upon the National Institute for health and
49 Care Excellence (NICE) health technology assessment framework. Crucial to cost-effectiveness
50 calculation is an assessment of how the disease affects health related quality of life (HRQoL). When
51 expressed over time as Quality Adjusted Life Years (QALYs) this permits standardised comparisons
52 between different healthcare interventions.

53 Cost effectiveness is often summarised by the incremental cost effectiveness ratio (ICER) which
54 represents the cost implications per net change in QALYs. In the UK, NICE suggests that an ICER less
55 than £20-30,000 per QALY is likely to be cost-effective. To fully capture the benefits of an
56 intervention, NICE recommends that all direct health benefits (not just those for the patient) should
57 be taken into account. Reviews have found that this is still a relatively uncommon practice, most
58 often applied in health economic assessments of chronic diseases with informal but long term caring
59 commitments such as dementia. [6-8]

60 Although there have been many assessments of the clinical burden[9–11] and secondary economic
61 costs to families,[12,13] the effects of rotavirus on HRQoL have not been robustly assessed. The
62 analyses of rotavirus vaccine cost effectiveness in the UK [14] as well as in other countries[15,16] are
63 based on data from a single cohort of attendances to Canadian primary care.[17] All found the QALY
64 loss of parents and children to be a major determining factor of vaccine cost effectiveness. As the
65 severity of cases seen in primary care may not be representative of the whole spectrum of rotavirus
66 disease, we sought to determine the effects of more severe rotavirus infection on the HRQoL of a
67 cohort of children and their parents in the UK to help provide additional data to parameterise any
68 future cost effectiveness analyses.

69 Methods

70 Children presenting with symptoms of gastroenteritis (>2 loose stools and/or >1 episode of forceful
71 vomiting in the last 24 hours) under six years of age were recruited from the paediatric emergency
72 department of Bristol Royal Hospital for Children. After obtaining informed consent, a short
73 questionnaire assessed childrens' and their carers' quality of life at the point of presentation to
74 hospital and asked for how long symptoms had been present. The impact of the child's illness on
75 the quality of life of the primary, and when present, secondary carer was assessed using the EQ5D-
76 5L[18] using UK 3L-5L crosswalk valuation sets for valuation[19]. Children's HRQoL was assessed
77 using the Health Utilities Index 2 (HUI2)[20] questionnaire with the addition of the EQ5D visual
78 analogue scale (VAS) which is anchored at 0 - "best health you can imagine" to 100- "worst health
79 you can imagine". Clinical severity was assessed using the Vesikari [21] scoring system. This scale
80 was developed for the assessment of rotavirus vaccines and combines the length and frequency of
81 symptoms, degree of dehydration and level of treatment required to assign a score between 0 and
82 20. In its derivation community cohort of children with rotavirus gastroenteritis the mean score was
83 11 (standard deviation 3.7); conventionally severe gastroenteritis is defined as a score greater than
84 10. A stool sample was collected and tested for viral causes of gastroenteritis using routine clinical
85 PCR. Families were asked to complete a daily diary card recording children's symptoms, days of

86 missed work, childcare and healthcare use until they felt their child had returned to normal health
87 (see appendix 1 for example page). At this point there was a final assessment of the whole family's
88 HRQoL and the diary was returned by post.

89 *Figure 1: Graphical representation of our method of estimating QALY loss.*

90 *Point A represents disease onset, point B assessment in the emergency department at nadir HRQoL.*
91 *Point C, recovery HRQoL – is assumed to represent pre-morbid baseline. Shaded area represents the*
92 *QALY loss due to rotavirus gastroenteritis.*

93 As rotavirus is usually a transient self limiting illness with no long term effects, we assumed that a
94 child's pre-morbid HRQoL would be the same as their HRQoL once they had recovered from the
95 acute illness. To calculate HRQoL loss we estimated a constant linear decrease from the pre-morbid
96 baseline at reported symptom start to a nadir at point of presentation to the emergency department
97 and then constant improvement to return to baseline by the reported end date. (Figure 1)

98 Any incomplete domains were scored as perfect health. Non parametric distributions were
99 compared using the Mann -Whitney U test. Confidence intervals for the mean were derived from
100 1000 bootstrap iterations. Statistical analyses were performed using R.[22]

101 The study was approved by the South West Central Bristol NRES ethics committee (REC12/SW/0359)
102 and funded through a University Hospitals Bristol NHS Foundation Trust Clinical PhD studentship.

103 **Results**

104 129 families consented to take part in the study, 118 (91%) completed the initial questionnaire and
105 59 (46%) returned the diary. Of the 84 (65%) found to be rotavirus positive, 77 completed the initial
106 questionnaire and 48 returned the diary. Childrens' median age was 14 months (IQR 10-22m) and
107 52% were male. Children had been ill for a mean 4 (95%CI 3.5-4.6) / median 4 (IQR 2-5) days before
108 attending the emergency department. 41 (53%) children required hospital admission. The mean

109 Vesikari score on attendance was 11.2 (SD 2.5 range 5-18) with 66% categorised as severe (score
 110 greater than 10).

		First assessment n=77		Final Assessment n=48	
		Mean	(95% CI)	Mean	(95% CI)
Child	HUI2	0.735	0.69 - 0.78	0.96	0.94- 0.98
	VAS	0.418	0.37 - 0.46	0.83	0.79- 0.88
Primary carer	EQ5D	0.68	0.61 - 0.74	0.86	0.81 - 0.92
	VAS	0.70	0.65- 0.75	0.84	0.80 - 0.89
Secondary carer	EQ5D	0.80	0.74 - 0.85	0.93	0.90 - 0.96
	VAS	0.79	0.73- 0.85	0.88	0.84 - 0.93

111 Table 1 of HRQoL of child & related adults

112 Table 1 shows the mean HRQoL of children and carers at presentation and at final assessment in
 113 those who returned diaries. At time of presentation to the emergency department, the main
 114 domains reported to be affected in children were emotion and pain, with 81% and 64% reporting
 115 reduced scores, respectively. In adults the main domains were usual activities and anxiety (with 64%
 116 and 62% of cases reporting reduced scores, respectively). There were no significant differences in
 117 reported initial HRQoL (p=0.72), disease severity (p=0.92), rate of admission (p=0.23) or length of
 118 illness prior to attendance (p=0.5) between those who did and did not return the diaries. Children
 119 whose parents returned the diaries tended to be slightly older (median 15.8 vs 11.1 months (p=0.06)
 120 than those who did not, but were not significantly different (p=0.2) from the total age distribution of
 121 gastroenteritis attendances to the Emergency Department. Families reported their children to
 122 remain ill for a mean 5.7 (95%CI 5.1- 6.5) / median of 5.5 (IQR 4-7) additional days following initial
 123 interview.

124 Parents were asked to self allocate as the primary (n=48) or secondary (n=41) carer. In all but one
 125 case (where there was a single father), the mother was recorded as primary carer. There were five
 126 single mothers families leaving 40 fathers and one grandmother recorded as secondary carers.

127 Within the completed diary cohort, at least one other member developed a secondary case of
 128 gastroenteritis in 52% of households. For working carers, 69% missed a mean 2.8 (95% CI 2.3-3.4),
 129 median 2.3 (IQR 1.4 -3.8) days of work.

130 For our primary analysis, in those who returned their diaries, we calculated QALY loss using the last
 131 reported HRQoL as baseline, i.e. we assumed that by the end of the study individuals had returned
 132 to normal health. For children this equated to a mean loss of 3.1 QALYs per thousand episodes, with
 133 mean loss for primary and secondary carers 2.7 and 2.1 QALYS per 1000 episodes respectively.

134 However 43% of families still reported their child to be unwell in free-text or using the VAS in their
 135 last diary entry. Concurrently 44% of carers still reported their HRQoL below standard healthy
 136 norms[23] and in free text ten (20%) parents noted that they were suffering from gastroenteritis
 137 themselves. To account for this, we carried out a sensitivity analysis (table 2) using the nadir HRQoL
 138 reported by all respondents (not just those returning the diaries) and compared it to baseline of
 139 perfect health in children and healthy adult UK EQ5D population standard values[23] for age and
 140 gender. This resulted in a higher estimated QALY loss for children and the primary carer, although
 141 confidence intervals overlapped with our primary estimates.

Analysis	Population	HRQoL comparisons	Mean QALY loss per thousand cases (95% CI)		
			Child	Primary carer	Secondary carer
Primary	Diary returners (n=48)	Difference in individual's first reported HRQoL to the final using triangular function (fig 1a)	3.1 (2.2-4.1)	2.7 (1.2-4.1)	2.1 (1.3-3.0)
Sensitivity	All respondents (n=77)	Difference in individual's first reported HRQoL compared to perfect health in children and population norm for adults	3.5 (2.9-4.1)	3.4 (2.5-4.3)	1.8 (1.0-2.7)

142

143 Table 2: Sensitivity analysis comparing our primary analysis to an alternative method of calculating
 144 the mean QALY loss / 1000 cases of rotavirus.

145

146

147 Comparing patients who could be discharged from the Emergency department to those that
 148 required admission(table 3) we found that families with children requiring admission all reported a
 149 trend towards a greater total QALY loss than those who could be discharged, 8.2 vs 4.6 (p=0.18) or 9
 150 vs 5.8 QALYS (p=0.08).

Population	HRQoL comparisons		Mean QALY loss per thousand cases (95% CI)			
			Child	Primary carer	Secondary carer	Family total
Primary analysis Diary returners (n=48)	Difference in individual's first reported HRQoL to the final using triangular function (fig 1a)	Admitted (n=24)	3.4 (1.5-5.3)	4.0 (1.6-6.4)	2.8 (1.7-3.9)	8.2 (4.7-11.7)
		Discharged (n=24)	2.9 (2.3-3.4)	1.4 (0.3-2.3)	1.5 (0.2-2.7)	4.6 (2.9-6.3)
		p=	0.91	0.60	0.05	0.18
Sensitivity analysis All respondents (n=77)	Difference in individual's first reported HRQoL compared to perfect health in children and population norm for adults	Admitted (n=36)	3.9 (2.9-4.8)	4.3 (2.8-5.6)	2.4 (1.0-3.7)	9.0 (6.7-11.3)
		Discharged (n=41)	3.0 (2.4-3.7)	2.3 (1.4-3.3)	1.3 (0.3-2.3)	5.8 (4.3-7.3)
		p=	0.33	0.71	0.13	0.08

151

152 Table 3: Sub-analysis comparing the mean QALY loss / 1000 cases of rotavirus between those who
 153 could be discharged from the emergency department and those who required admission.

154

155 **Discussion**

156 This is the first attempt to measure the number of Quality Adjusted Life Years lost due to acute
157 severe rotavirus gastroenteritis in the UK. We have found the QALY loss of children with acute
158 rotavirus attending the paediatric emergency department to be 3.1-3.5 per 1000 cases. The QALY
159 loss per thousand primary / secondary carers was 2.7-3.4 and 1.8-2.1 respectively.

160 There are just three published studies using a parentally reported preference based method to
161 assess HRQoL during rotavirus infection and only one calculates total QALY loss. A Canadian study of
162 rotavirus burden[24] examined 395 children under the age of three years presenting for outpatient
163 paediatric care. A separately reported HRQoL arm[17] used the HUI2 to assess children and EQ5D
164 for parents at presentation, day 7 and day 14. This found nadir HRQoL of 0.896 (0.874; 0.917) for
165 children and 0.875(0.844; 0.907) for parents. Comparing to a baseline reported HRQoL at day 14
166 they estimated a QALY loss of 2.2 (95% CI: 1.7; 2.7) and 1.8 (95% CI: 1.0; 2.7) per thousand affected
167 children and parents respectively. This figure was used for all cases seeking medical attention in the
168 cost-effectiveness model[14] instrumental in the UK's 2012 decision to introduction of RV vaccine.
169 Two further studies report the HRQoL at presentation with rotavirus gastroenteritis. Both used the
170 EQ5D for both parent and child (despite there being no validated value sets for children). The first
171 study from Thailand [25] examined hospitalised children and rated the mean child's utility as 0.604
172 (95%CI: 0.592, 0.615) and parents of 0.618 (95%CI: 0.606, 0.629). The second study from
173 Denmark[26] of all gastroenteritis attendances found median HRQoL of 0.7123 for children, and
174 0.818 for parents with a median length of illness of 7 days. This was lower in those who required
175 hospitalisation for both the child (0.531) and their parent (0.743) although no significance testing or
176 confidence intervals were reported.

177 Between countries, different attitudes to health seeking behaviour and accessibility to health
178 services will dictate the severity of cases seen in a particular healthcare setting. In the UK, with the
179 re-organisation of primary care provision, increasing numbers of families now present directly to

180 the Emergency Department for minor medical illnesses.[27] Thus paediatric emergency
181 departments have a very varied case mix, providing both primary care to self-referrals as well as
182 secondary assessments of more severe cases. Within our cohort only 12% had been referred to
183 hospital by their GP, yet 60% reported that they had already consulted their GP at least once during
184 the episode. Despite 53% requiring admission, our cohort's mean HRQoL was significantly higher
185 than Thai inpatients ($p < 0.001$), and most similar to those reported from Danish primary care. Both
186 our HRQoL ($p < 0.001$) and sensitivity QALY loss ($p < 0.001$) estimates are significantly greater than
187 those measured by Brisson et al[17]. Although underpowered, our subgroup analysis suggests that
188 even patients that could be discharged from the emergency department have a greater QALY loss
189 than in Canadian primary care; with those requiring admission reporting a trend towards greater
190 effects.

191 The main limitation of our study is that in an effort to reduce the burden on families already looking
192 after sick children, rather than require daily diary entry for a fixed period, we allowed carers to
193 report when they considered their child to be recovered and return the diary at that point. It was
194 hoped that this would improve our diary response rate. However despite clear instructions and
195 reminders, many families returned the diaries as soon as diarrhoea had ceased, while commenting
196 that their child had not yet returned to normal in the free text and VAS score. As such our data may
197 both underestimate the length of illness and give a falsely low end baseline HRQoL; to address this
198 we used alternative baselines in a sensitivity analysis, which resulted in slightly higher estimated
199 QALY losses. Our measure of carer HRQoL is likely to have captured both the worry/stress of caring
200 for their child and also any effects of them becoming ill themselves during the time window during
201 which their child was ill. Adult measurements were taken at the (assumed) peak and resolution of
202 child's illness – which will not necessarily correspond to the time course of a carer's disease. Thus
203 carers' QALY loss may well be an underestimate in those who became ill as any acute deterioration is
204 unlikely to have been detected by our method. The differences seen between carers are interesting.
205 By definition the primary carer will have spent more time caring for the ill child, so it is perhaps not

206 surprising that they felt their quality of life was more affected than the other parent, however the
 207 proportion of reported secondary illness was not significantly different 32%/34% ($p=1.0$) between
 208 carers.

209 In contrast to adults, estimating the HRQoL of pre-school children is problematic[28] as there is
 210 simply no validated instrument for this specific age group. We chose to use parentally reported
 211 HUI2 as although designed for children over the age of five, it has previously been recommended by
 212 NICE[29], UK specific values have been developed[30] and it was the method used in the most
 213 widely cited assessment in the literature.[17] This allows direct comparison of our data with those
 214 results, and may explain some of the difference in comparison with studies using the adult EQ5D
 215 instrument for children.

216 In comparison to other vaccine preventable diseases (table 4) our findings suggest that on average,
 217 an individual episode of rotavirus has only a relatively small HRQoL impact. However the ubiquitous
 218 nature of this disease means that this represents a significant population burden especially when the
 219 effects on carers are included.

220 With an increasing number of vaccines being developed but finite healthcare resources, the decision
 221 of which ones to introduce can become problematic. For well informed recommendations using our
 222 current cost per QALY approach; it is essential that there are accurate data characterising the burden
 223 of common childhood illness being collected.

Disease	Child's QALY loss/1000 cases	Incidence in children by age 5
Rotavirus	3.1-3.5	98%[1]
Pneumonia[31]	4	
Chickenpox[32]	4	45%[32]
Influenza[33]	8	67%[34]
Measles[35]	19	<1% with vaccine
Pertussis[36]	97	<1% with vaccine
Meningococcal disease (cases without sequelae)[37]	200	0.05%[38]

224 Table 4 – QALY loss for childhood vaccine preventable diseases.

225

226 **Conclusions**

227 Our results suggest that RV gastroenteritis has a significantly higher impact on the quality of life of
228 children and their carers in the UK than previously reported in studies done elsewhere. The results
229 of the first year of vaccination in the UK appear to show a large reduction in rates of disease[39].

230 Our findings imply the programme will have been more cost effective than previously estimated,
231 since the QALY losses we show in children presenting to the Emergency Department and their
232 families are higher than the estimates used in the cost effectiveness studies which drove the
233 recommendation to introduce the vaccine. These figures may be of value to other European
234 countries still evaluating the cost-effectiveness of introducing rotavirus vaccination.

235 **Acknowledgements**

236 The study was supported by the NIHR Health Protection Research Unit in Evaluation of
237 Interventions. The views expressed are those of the author(s) and not necessarily those of the NHS,
238 the NIHR, the Department of Health or Public Health England

239 **Source of funding**

240 RM is funded by a University Hospitals Bristol PhD Fellowship.

241 **Conflicts of interest**

242 RM has received travel bursaries from GSK to attend educational meetings. AF undertakes
243 consultancy and clinical research for all the main vaccine companies, the fees payable to the
244 University of Bristol and University Hospitals Bristol NHS Foundation Trust. CT received a consulting
245 payment from GSK in 2013 for critical review of a health economic model of meningococcal vaccines.

246

247 **References**

- 248 [1] Marlow RD, Finn A. The promise of immunisation against rotavirus. *Arch Dis Child*
 249 2012;97:736–40. doi:10.1136/archdischild-2011-301472.
- 250 [2] Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of
 251 worldwide rotavirus-associated mortality in children younger than 5 years before the
 252 introduction of universal rotavirus vaccination programmes: a systematic review and meta-
 253 analysis. *Lancet Infect Dis* 2012;12:136–41. doi:10.1016/S1473-3099(11)70253-5.
- 254 [3] De Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young
 255 children: rotavirus and cholera immunization. *Bull World Health Organ* 1985;63:569–83.
- 256 [4] WHO | 18 December 2009, vol. 84, 50 (pp 533–540) n.d.
 257 http://www.who.int/wer/2009/wer8451_52/en/index.html (accessed October 25, 2010).
- 258 [5] Jit M, Pebody R, Chen M, Andrews N, Edmunds WJ. Estimating the number of deaths with
 259 rotavirus as a cause in England and Wales. *Hum Vaccin* 2007;3:23–6.
- 260 [6] Goodrich K, Kaambwa B, Al-Janabi H. The inclusion of informal care in applied economic
 261 evaluation: a review. *Value Health J Int Soc Pharmacoeconomics Outcomes Res* 2012;15:975–
 262 81. doi:10.1016/j.jval.2012.05.009.
- 263 [7] Wittenberg E, Prosser LA. Disutility of illness for caregivers and families: a systematic review of
 264 the literature. *Pharmacoeconomics* 2013;31:489–500. doi:10.1007/s40273-013-0040-y.
- 265 [8] Krol M, Papenburg J, van Exel J. Does including informal care in economic evaluations matter?
 266 A systematic review of inclusion and impact of informal care in cost-effectiveness studies.
 267 *Pharmacoeconomics* 2015;33:123–35. doi:10.1007/s40273-014-0218-y.
- 268 [9] Harris JP, Jit M, Cooper D, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales.
 269 Part I. Estimating the burden of disease. *Vaccine* 2007;25:3962–70.
 270 doi:10.1016/j.vaccine.2007.02.072.
- 271 [10] Iturriza Gomara M, Simpson R, Perault AM, Redpath C, Lorgelly P, Joshi D, et al. Structured
 272 surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common
 273 viral gastroenteric pathogens. *Epidemiol Infect* 2008;136:23–33.
 274 doi:10.1017/S0950268807008059.
- 275 [11] Iturriza-Gómara M, Elliot AJ, Dockery C, Fleming DM, Gray JJ. Structured surveillance of
 276 infectious intestinal disease in pre-school children in the community: “The Nappy Study.”
 277 *Epidemiol Infect* 2009;137:922–31. doi:10.1017/S0950268808001556.
- 278 [12] Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M, REVEAL Study Group. Costs
 279 of Community-Acquired Pediatric Rotavirus Gastroenteritis in 7 European Countries: The
 280 REVEAL Study. *J Infect Dis* 2007;195:S36–44. doi:10.1086/516716.
- 281 [13] Lorgelly PK, Joshi D, Iturriza Gómara M, Flood C, Hughes CA, Dalrymple J, et al. Infantile
 282 gastroenteritis in the community: a cost-of-illness study. *Epidemiol Infect* 2008;136:34–43.
 283 doi:10.1017/S0950268807008163.
- 284 [14] Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The
 285 potential cost-effectiveness of vaccination. *Vaccine* 2007;25:3971–9.
 286 doi:10.1016/j.vaccine.2007.02.070.
- 287 [15] Newall A.T., Beutels P., Macartney K., Wood J., MacIntyre C.R. The cost-effectiveness of
 288 rotavirus vaccination in Australia. *Vaccine* 2007.
- 289 [16] Bilcke J, Damme PV, Beutels P. Cost-Effectiveness of Rotavirus Vaccination: Exploring
 290 Caregiver(s) and “No Medical Care” Disease Impact in Belgium. *Med Decis Making*
 291 2009;29:33–50. doi:10.1177/0272989X08324955.
- 292 [17] Brisson M, Sénécal M, Drolet M, Mansi JA. Health-Related Quality Of Life Lost To Rotavirus-
 293 Associated Gastroenteritis In Children And Their Parents. *Pediatr Infect Dis J* 2010;29:73–5.
 294 doi:10.1097/INF.0b013e3181b41506.
- 295 [18] EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life.
 296 *Health Policy Amst Neth* 1990;16:199–208.

- 297 [19] Van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring
 298 for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health J Int Soc*
 299 *Pharmacoeconomics Outcomes Res* 2012;15:708–15. doi:10.1016/j.jval.2012.02.008.
- 300 [20] Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function
 301 for a comprehensive health status classification system. *Health Utilities Index Mark 2. Med*
 302 *Care* 1996;34:702–22.
- 303 [21] Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical
 304 severity of diarrhoeal episodes. *Scand J Infect Dis* 1990;22:259–67.
- 305 [22] R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R
 306 Foundation for Statistical Computing; 2014.
- 307 [23] Kind P, Hardman G, Macran S. *UK population norms for EQ-5D*. Centre for Health Economics,
 308 University of York; 1999.
- 309 [24] Sénécal M, Brisson M, Lebel MH, Yaremko J, Wong R, Gallant LA, et al. Measuring the Impact of
 310 Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study.
 311 *Can J Infect Dis Med Microbiol* 2008;19:397–404.
- 312 [25] Rochanathimoke O, Postma M, Thavorncharoensap M, Riewpaiboon A, Thinyoung W.
 313 PGI35 - Quality Of Life Of Diarrheal Children And Caregivers In Thailand. *Value Health*
 314 2014;17:A368–9. doi:10.1016/j.jval.2014.08.832.
- 315 [26] Hoffmann T, Iturriza M, Faaborg-Andersen J, Kraaer C, Nielsen CP, Gray J, et al. Prospective
 316 study of the burden of rotavirus gastroenteritis in Danish children and their families. *Eur J*
 317 *Pediatr* 2011;170:1535–9. doi:10.1007/s00431-011-1465-y.
- 318 [27] Sands R, Shanmugavadeivel D, Stephenson T, Wood D. Medical problems presenting to
 319 paediatric emergency departments: 10 years on. *Emerg Med J EMJ* 2012;29:379–82.
 320 doi:10.1136/emj.2010.106229.
- 321 [28] Grange A, Bekker H, Noyes J, Langley P. Adequacy of health-related quality of life measures in
 322 children under 5 years old: systematic review. *J Adv Nurs* 2007;59:197–220.
 323 doi:10.1111/j.1365-2648.2007.04333.x.
- 324 [29] National Institute for Health and Clinical Excellence. *Guide to the methods of technology*
 325 *appraisal*. 2008.
- 326 [30] McCabe CJ, Stevens KJ, Brazier JE. Utility scores for the Health Utilities Index Mark 2: an
 327 empirical assessment of alternative mapping functions. *Med Care* 2005;43:627–35.
- 328 [31] Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination
 329 in England and Wales. *Vaccine* 2004;22:4203–14. doi:10.1016/j.vaccine.2004.05.003.
- 330 [32] Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. *Arch*
 331 *Dis Child* 2003;88:862–9. doi:10.1136/ad.88.10.862.
- 332 [33] Van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza
 333 H1N1 on health-related quality of life: a prospective population-based study. *PloS One*
 334 2011;6:e17030. doi:10.1371/journal.pone.0017030.
- 335 [34] Sauerbrei A, Langenhan T, Brandstädt A, Schmidt-Ott R, Krumbholz A, Girschick H, et al.
 336 Prevalence of antibodies against influenza A and B viruses in children in Germany, 2008 to
 337 2010. *Euro Surveill* 2014;19.
- 338 [35] Thorrington D, Ramsay M, van Hoek AJ, Edmunds WJ, Vivancos R, Bukasa A, et al. The Effect of
 339 Measles on Health-Related Quality of Life: A Patient-Based Survey. *PLoS ONE* 2014;9:e105153.
 340 doi:10.1371/journal.pone.0105153.
- 341 [36] Van Hoek AJ, Campbell H, Andrews N, Vasconcelos M, Amirthalingam G, Miller E. The Burden
 342 of Disease and Health Care Use among Pertussis Cases in School Aged Children and Adults in
 343 England and Wales; A Patient Survey. *PLoS ONE* 2014;9. doi:10.1371/journal.pone.0111807.
- 344 [37] Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of
 345 universal meningitis vaccination (Bexsero) in England: modelling study. *BMJ* 2014;349:g5725–
 346 g5725. doi:10.1136/bmj.g5725.

- 347 [38] Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive
348 meningococcal disease in England and Wales: implications for the introduction of new
349 vaccines. *Vaccine* 2012;30:3710–6. doi:10.1016/j.vaccine.2012.03.011.
- 350 [39] Marlow R.D., Muir P, Vipond B, Trotter C, Finn A. Assessing the impacts from one year of
351 rotavirus vaccination in the UK. *Eurosurveillance* 2015;accepted.
- 352